Delgocitinib is an investigational Janus kinase (JAK) inhibitor being studied for its potential to treat conditions such as atopic dermatitis [1]. The patent US8609647B2, related to delgocitinib, is described in Google Patents [2].
What is Delgocitinib's Patent Status?
The patent US8609647B2, assigned to Mitsubishi Tanabe Pharma Corporation, covers methods of treating inflammatory diseases using a specific chemical compound [2]. DrugPatentWatch.com tracks patent information for pharmaceutical compounds, including delgocitinib [1]. Understanding patent timelines is crucial for the development and market entry of generic or biosimilar alternatives [1].
When Does Delgocitinib's Patent Protection End?
Information regarding the specific expiration date for US8609647B2 is available through patent databases [2]. Generally, patent terms for pharmaceuticals are designed to provide a period of market exclusivity [1]. DrugPatentWatch.com provides detailed patent expiration information, which is essential for assessing potential market entry dates for competing products [1].
How Does Delgocitinib Work?
Delgocitinib functions as a Janus kinase (JAK) inhibitor [1]. JAKs are intracellular enzymes involved in signaling pathways that mediate immune responses and inflammation. By inhibiting JAKs, delgocitinib aims to reduce the inflammatory processes associated with certain diseases [1].
What Conditions is Delgocitinib Being Developed For?
Delgocitinib is primarily being investigated for the treatment of inflammatory conditions, with a notable focus on atopic dermatitis [1]. Clinical trials are ongoing to evaluate its efficacy and safety for these indications [1].
Who is Developing Delgocitinib?
Mitsubishi Tanabe Pharma Corporation is the entity associated with the patent US8609647B2 for delgocitinib [2]. They are leading the research and development efforts for this drug candidate [1].
What are the Risks Associated with JAK Inhibitors?
As a class, JAK inhibitors have been associated with certain safety considerations, including an increased risk of serious infections, cardiovascular events, thrombosis, and malignancies [1]. The specific risk profile for delgocitinib is being evaluated through clinical trials [1].
Are There Other Drugs Like Delgocitinib?
Delgocitinib belongs to the class of JAK inhibitors, a group that includes other approved medications used for various inflammatory and autoimmune conditions [1]. The therapeutic landscape for inflammatory diseases is competitive, with multiple treatment options available or in development [1].
Where Can I Find More Patent Information?
Detailed patent information, including the status and expiration of US8609647B2, can be accessed through patent search engines like Google Patents [2]. Resources such as DrugPatentWatch.com offer comprehensive data on drug patents and market exclusivity [1].
What is Atopic Dermatitis?
Atopic dermatitis, also known as eczema, is a chronic inflammatory skin condition characterized by itchy, red, and inflamed skin [1]. It often affects individuals with a history of asthma or hay fever [1].
Sources:
[1] DrugPatentWatch.com
[2] Google Patents